See if you are eligible to participate in a study evaluating an investigational drug for the treatment of liver fibrosis in adult patients who have non-alcoholic steatohepatitis (NASH). To qualify you must:

• be between the ages of 18 and 75
• Have had a liver biopsy or be willing to undergo a liver biopsy

Qualified participants may receive:

Ask us about your liver.
National Research Institute
877.719.6767
14418 Chase Street #200
Panorama CIty, CA 91402

Have you ever been told you have or are at risk for fat deposited in your liver?

• Have you had abnormal lab tests?
• Are you overweight?
• Have you ever told you are at risk for or have diabetes?
• Do you have a family history of liver disease related to fatty liver?

Ask us about your liver.
National Research Institute
877.719.6767
14418 Chase Street #200
Panorama CIty, CA 91402

This study will use an imagoing technique called LiverMultiscan to see if HTD1801 helps to treat NASH. HighTIDE Biopharma Pty. Ltd (Hightide) is the sponsor of this study.

• Non-invasive technique, safe and painless
• Accurately measures liver fat, as well as iron and inflammation that may indicate a level of liver disease
• Analysis of liver to assess variations in disease condition
• Scans completed in 15 minutes

Ask us about your liver.
National Research Institute
877.719.6767
14418 Chase Street #200
Panorama CIty, CA 91402

NASH is an advanced form of fatty liver disease called non-alcoholic steato-hepatitis.

If you have NASH you may be able to participate in this research study. If you qualify, your participation will last up to 6 years with up to 8 office visits in the first year and a half and 2 office visits every year following.

Study drug, study-related and all study tests will be provided at no charge. Eligible participants may also be reimbursed for travel expenses.